Suven Life Sciences Share Price Today

Suven completes Phase-3 enrolment for masupirdine with 424 patients

Suven Life Sciences completed enrolment in its global Phase-3 masupirdine trial for Alzheimer's agitation. A total of 424 patients were randomized, exceeding the original design target of approximately 375 patients. The study is conducted across sites in the USA and Europe with a double-blind, placebo-controlled design. Last patient last visit is expected by end of December 2026, with database lock by March 2027. Topline results are anticipated by May 2027.

Suven Life Sciences shareholders approve all 37th AGM resolutions

Suven Life Sciences shareholders passed all five resolutions at the 37th AGM on August 25, 2026. Financial statements for FY26 were adopted with 99.99% shareholder support. Shareholders approved related-party transaction for MD appointment in overseas subsidiaries. Variation in preferential issue fund utilization received 99.98% approval. Promoter group abstained from voting on the conflicted related-party resolution.

Suven Life Sciences Q1FY27 net loss widens to ₹1,276 crore

Suven Life Sciences Ltd reported a widened consolidated net loss of ₹1,276.10 crore for Q1FY27, driven by a 198.5% surge in R&D expenses to ₹1,238.31 crore. While operational revenue grew 90% to ₹35.66 crore, the company remains heavily reliant on capital reserves and other income to fund its pre-revenue CNS drug discovery activities.

Alzheimer's market to hit USD 4 billion in 2025 as pipeline expands

The Alzheimer's disease market is valued at USD 4 billion in 2025, with a projected 22.7% CAGR through 2036. Growth is driven by disease-modifying therapies like LEQEMBI and emerging pipeline candidates. Suven Life Sciences' Masupirdine is advancing in Phase III trials for agitation, joining other key therapies from Roche, Axsome Therapeutics, Bristol Myers Squibb, Eli Lilly, and Annovis Bio in reshaping treatment landscapes.

Suven Life Sciences files BRSR for FY26, reports 70% export revenue

Suven Life Sciences Limited disclosed its FY26 sustainability metrics, noting 70% export revenue and improved employee retention. Environmental data shows rising energy use and GHG emissions, while safety records remain clean with zero incidents. The report was assured by J. Sundharesan & Associates.

Suven Life Sciences seeks AGM approval for related party transaction and fund reallocation

Suven Life Sciences has issued its 37th AGM notice for August 25, 2026, seeking approval for a material related party transaction appointing Dr. Madhavi Jasti and reallocating unutilised preferential issue proceeds from CAPEX to clinical development. The meeting also addresses the re-appointment of an Independent Director beyond age 75 against a backdrop of widened FY26 losses.